www.drugdevelopment-technology.com
News, views and contacts from the global Drugdevelopment industry
31 March 2017
WEEKLY UPDATE
Digital Magazine
Latest Companies

Biovian - Contract Manufacturing Of Biopharmaceuticals

Sartorius - Biopharmaceutical Laboratory Equipment and Integrated Bioprocess Services

Pharmatest Services - Research Models to Evaluate Drug Candidate Efficacy

ImmunoPrecise Antibodies - Custom Monoclonal and Polyclonal Antibody Development

Softigel - Contract Development Services and Drug Delivery Systems

Press Releases

Pharmatest to Host Seven Presentations at AACR in Washington, US
Pharmatest Services has announced it will attend the annual meeting of American Association for Cancer Research (AACR) in Washington, US.

Shin-Etsu Purchase Gamlen D Series for Formulation Studies
Provider of a wide range of cellulose ether excipients Shin-Etsu PFMD has purchased a Gamlen D series powder compaction analyser for a laboratory application in Wiesbaden, Germany.

Malvern March Webinars
Malvern is hosting two webinars this month: Differential scanning calorimetry (robust and powerful physical characterisation of therapeutic protein products) and Cement (composition, structure, and fineness - we are stronger together!).

Pharmatest Joins Biocom and Science Exchange Life Science Organisations in California
Pharmatest Services has announced it has joined two California-based organisations Biocom and Science Exchange.

Malvern to Host Webinar on Characterisation and Optimisation of Particle Size and Shape of Metal Powders
Efficiency of the production process of powder bed additives is reliant on packing density and flow behaviour of metal powders involved.

White Papers

Optimising Development Resources for Efficient Product Development
Development departments suffer from a shortage of resources and are often overburdened with administration...

Validated Metal Analysis
Four commonly utilized carbohydrates for ptotein stabilization are Sucrose, Trehalose, Mannitol, and...

Evaluating API and Excipient Characteristics for Tablet Formulations
Before tablet formulations are designed, any active pharmaceutical ingredients (API) and excipients should be fully understood in terms of their compressibility, compactability, and...

Improving OMNISEC Results by Switching Mobile Phases
Polylactic and polyglycolic acid are used for a number of applications including biomedical applications. Absorbable sutures, medical implant hardware, food packaging, and clothing all...

Benefits of Trehalose
Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of...

Features

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial
Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v to prevent mosquito-transmitted diseases. Drugdevelopment-technology.com wraps up the key headlines from February.

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk
TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopment-technology.com wraps-up the key headlines from January.

2016: The year's biggest Drug Development Technology stories
NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016.

November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial
UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November.

October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child
Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016.

Projects

Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer
Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer in post-menopausal women.

Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes
Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes.

Alecensa (alectinib) for Treatment of ALK-positive Non-small Cell Lung Cancer
Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy
Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for the treatment of patients aged five and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals.

Symbicort (budesonide and formoterol) for the Treatment of Asthma
Symbicort (budesonide and formoterol) is an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) indicated for the treatment of asthma in paediatric patients aged between six and 12 years. The drug was discovered and developed by AstraZeneca.

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.